Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report issued on Friday morning. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright dropped their price target on Aethlon Medical from $10.00 to $7.00 and set a buy rating on the stock in a research note on Monday, June 24th.

Aethlon Medical Stock Performance

Shares of NASDAQ:AEMD opened at $0.38 on Friday. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $2.84. The business has a 50-day simple moving average of $0.39 and a two-hundred day simple moving average of $0.87. The firm has a market cap of $5.35 million, a price-to-earnings ratio of -0.08 and a beta of 1.72.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.10. During the same quarter in the prior year, the business earned ($1.30) earnings per share. As a group, research analysts predict that Aethlon Medical will post -1.1 earnings per share for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.